2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1730

IL-6 Mediates Activation of Macrophages in Patients with Systemic Sclerosis
Abstract Number: 1795

IL-7 in Primary Sjogren Syndrome (pSS) Is Secreted By Salivary Gland Epithelial Cells after IFN Stimulation and Is Associated with B-Cell Activation
Abstract Number: 864

IL-9-Producing Innate Lymphoid Cells – Keyplayers That Orchestrate Resolution of Chronic Inflammation in Arthritis
Abstract Number: 940

IL1RN Variation Is Associated with Systemic Juvenile Idiopathic Arthritis and Predicts Non-Response to Anakinra Treatment
Abstract Number: 2571

IL23 Deficiency Alters Thymic Selection in Lupus Prone Mice
Abstract Number: 594

Imaging Biomarkers in Crohn’s Associated Axial Spondyloarthritis
Abstract Number: 259

Imaging for Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Review of the Literature and Meta-Analysis Informing the EULAR Recommendations
Abstract Number: 850

Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System
Abstract Number: 2641

Immune Complex-Driven Neutrophil Activation in Systemic Lupus Erythematosus – Novel Biomarkers of Disease Activity and Severity
Abstract Number: 566

Immune Response to Seasonal Flu Vaccination in Patients with Primary Sjogren’s Syndrome
Abstract Number: 1325

Immune Responses to Peptides Containing Homocitrulline or Citrulline in the DR4-Transgenic Mouse Model of Rheumatoid Arthritis
Abstract Number: 2106

Immune-Related Adverse Events in Cancer Patients Treated with Immune Check Point Inhibitors: A Single Center Experience
Abstract Number: 481

Immunocompetent Cells Expressing Citrullinated Proteins in Joint Synovium of Osteoarthritis and Rheumatoid Arthritis
Abstract Number: 2415

Immunogenicity and Persistence of a Prime-Boost Re-Vaccination Strategy for Pneumococcal Vaccines (13-Valent Pneumococcal Conjugate Vaccine + 23-Valent Pneumococcal Polysaccharide Vaccine) in Patients with Rheumatoid Arthritis: A Pilot Study
Abstract Number: 383

Immunogenicity of 13 Valent Pneumococcal Vaccine in Children with Lupus: Single Center Experience in South Texas

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].